Table 3

Chemokine scores by presence or absence of SLE clinical features

Clinical features

SLE clinical features present

SLE clinical features absent

P

n

Median (interquartile range)

n

Median (interquartile range)

Renal

36

8.32 (1.43 to 19.41)

31

3.39 (-1.43 to +12.48)

NS

Neurological

4

1.27 (-0.65 to +4.17)

63

6.23 (-0.42 to +15.60)

NS

Arthritis

12

5.09 (-2.48 to +13.98)

55

5.93 (0.12 to 14.01)

NS

Serositis

13

5.47 (0.67 to 38.08)

54

5.32 (-0.93 to +13.96)

NS

Rash

22

2.37 (-2.27 to +13.96)

45

7.39 (0.89 to 15.634)

NS

Mucosal ulcer

8

4.21 (1.95 to 14.33)

59

5.93 (-4.46 to +14.01)

NS

Haematological

19

7.39 (-2.77 to +13.91)

48

5.09 (0.59 to 14.81)

NS

Proteinuria

26

8.511 (2.01 to 23.25)

41

3.39 (-1.56 to +12.56)

NS

Autoantibodies

Anti-dsDNA

37

5.47 (-0.32 to +14.17)

30

5.72 (-0.44 to +14.81)

NS

Anti-Ro

24

6.05 (1.85 to 13.96)

43

5.47 (-1.76 to +15.69)

NS

Anti-Sm

13

11.56 (3.89 to 23.82)

54

3.56 (-1.72 to +12.66)

0.0211

Anti-RNP

23

10.28 (3.08 to 18.97)

44

2.95 (-1.72 to +12.56)

0.0212

Anti-nucleosome

24

7.50 (1.63 to 15.69)

43

3.73 (-0.46 to +13.91)

NS

Medical therapy

Predisone dose >30 mg/day

38

4.76 (-1.56 to +12.66)

29

7.72 (2.12 to 19.89)

NS

Immunosuppressants

28

9.98 (0.53 to 17.33)

39

3.08 (-1.43 to +12.65)

NS

CQ/HCQ

28

2.15 (-1.72 to +12.11)

39

8.92 (2.34 to 18.97)

0.0481

anti-dsDNA, anti-double-stranded DNA; CQ, chloroquine; HCQ, hydrochloroquine; NS, not significant; SLE, systemic lupus erythematosus.

Fu et al. Arthritis Research & Therapy 2008 10:R112   doi:10.1186/ar2510